| Literature DB >> 25640077 |
Hao-Jui Weng1, Kush N Patel2, Nathaniel A Jeske3, Sonya M Bierbower3, Wangyuan Zou4, Vinod Tiwari5, Qin Zheng2, Zongxiang Tang6, Gary C H Mo7, Yan Wang8, Yixun Geng2, Jin Zhang9, Yun Guan5, Armen N Akopian10, Xinzhong Dong11.
Abstract
TRPA1 and TRPV1 are crucial pain mediators, but how their interaction contributes to persistent pain is unknown. Here, we identify Tmem100 as a potentiating modulator of TRPA1-V1 complexes. Tmem100 is coexpressed and forms a complex with TRPA1 and TRPV1 in DRG neurons. Tmem100-deficient mice show a reduction in inflammatory mechanical hyperalgesia and TRPA1- but not TRPV1-mediated pain. Single-channel recording in a heterologous system reveals that Tmem100 selectively potentiates TRPA1 activity in a TRPV1-dependent manner. Mechanistically, Tmem100 weakens the association of TRPA1 and TRPV1, thereby releasing the inhibition of TRPA1 by TRPV1. A Tmem100 mutant, Tmem100-3Q, exerts the opposite effect; i.e., it enhances the association of TRPA1 and TRPV1 and strongly inhibits TRPA1. Strikingly, a cell-permeable peptide (CPP) containing the C-terminal sequence of Tmem100-3Q mimics its effect and inhibits persistent pain. Our study unveils a context-dependent modulation of the TRPA1-V1 complex, and Tmem100-3Q CPP is a promising pain therapy.Entities:
Mesh：
Substances：
Year: 2015 PMID： 25640077 PMCID： PMC4336228 DOI： 10.1016/j.neuron.2014.12.065
Source DB: PubMed Journal: Neuron ISSN： 0896-6273 Impact factor: 17.173